– USA, MD – REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board of directors.
“David’s expertise in clinical research and development, as well as his experience advancing therapies through the regulatory process to FDA approval, will be of great value as REGENXBIO prepares to advance gene therapy treatments into the clinic,” said Don Hayden, Chairman of REGENXBIO’s board of directors. “We welcome him to the REGENXBIO board.”
Dr. Stump has more than 20 years of biopharmaceutical leadership experience. Most recently, Dr. Stump was Executive Vice President, Research and Development at Human Genome Sciences, Inc. Prior to joining Human Genome Sciences, Dr. Stump served in roles of increasing responsibility at Genentech, Inc., including Vice President, Clinical Research and as a Genentech Fellow. Dr. Stump began his career as an Associate Professor of Medicine and Biochemistry at the University of Vermont.
“REGENXBIO’s proprietary NAV Technology Platform has generated gene therapy treatments with the potential to transform the lives of patients suffering from severe diseases with significant unmet medical needs,” said Dr. Stump. “I look forward to working with REGENXBIO to successfully advance its gene therapy treatments into clinical development and expand the pipeline of AAV gene therapies.”
Dr. Stump earned an A.B. from Earlham College and an M.D. from Indiana University, followed by residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa, and further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. He is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology at the American Heart Association. He also serves as a member of the boards of directors at Portola Pharmaceuticals, Inc., MacroGenics, Inc. and Sunesis Pharmaceuticals, Inc., as well as on the board of trustees of Earlham College.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. REGENXBIO’s NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed candidates and 18 partnered candidates developed by REGENXBIO’s licensees.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.